Previous 10 | Next 10 |
home / stock / aplif / aplif news
Appili Therapeutics Inc. (TSX:APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company developing anti-infective drug candidates, today announced its financial and operational results for the second quarter of its fiscal year 2022, which e...
Appili Therapeutics (OTCQX:APLIF) announces that the company's oral antiviral Avigan/Reeqonus (favipiravir) failed to meet the primary endpoint in a late-stage trial for the treatment of mild-to-moderate COVID-19. The Phase 3 PRESECO (PREventing SEvere COVID-19 Disease) study i...
Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases, today announced that the Phase 3 PRESECO (PREventing SEvere COVID-19) clinical trial evaluating or...
AiPharma Enters into Strategic Alliance and Stock Swap Agreement with Appili Therapeutics - Strategic alliance will accelerate global development of broad spectrum antiviral oral medicine Avigan®/Reeqonus™ (favipiravir) for the treatment of COVID-19 and other infecti...
Strategic alliance for the global development of oral antiviral medicine Avigan®/Reeqonus TM (favipiravir) for the treatment of COVID-19 and other infectious disease programs New agreement with existing consortium partner AiPharma enhances complementary skills and cre...
More than 1,200 patients enrolled in the United States, Mexico, and Brazil Study expected to include patients with top priority COVID-19 variants, including Delta Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appil...
New Funds Will Help Expedite Completion of Recently Expanded Pivotal Phase 3 Study on Oral Antiviral Medicine Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development f...
Viral shedding sub-study to assess efficacy against recent COVID-19 variants, including Delta Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious di...
Capital Markets Veteran Josef Vejvoda to Join Appili Board of Directors as New Director Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases...
Appili Therapeutics Inc. (TSX:APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company developing anti-infective drug candidates, today announced its financial and operational results for the first quarter of its fiscal year 2022, which en...
News, Short Squeeze, Breakout and More Instantly...
Appili Therapeutics Inc Company Name:
APLIF Stock Symbol:
OTCMKTS Market:
Appili Therapeutics Inc Website:
Appili, with a commercial-stage pipeline, has raised CAD $100M towards developing therapeutics for the global infectious disease and biodefense markets. Subject to the renewal of certain legislation, two programs are potentially eligible for FDA Priority Review Vouchers Aditxt, Inc. (...
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, July 18, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “ Company ” or “ Appili ”), a biopharmace...
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, July 02, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “ Company ” or “ Appili ”), a biopharmace...